Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview

Lexicon Pharmaceuticals

04/08/2026 15:03

Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The The Woodlands Texas-based  company is expected to report a 86.1% decrease in revenue to $3.998 million from $28.87 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 5 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.10, about 33% above its last closing price of $2.33
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.03
-0.03
0.00
Beat
100
Dec. 31 2026
-0.07
-0.07
-0.04
Beat
42
Sep. 30 2025
-0.05
-0.07
-0.04
Beat
39.4​
Jun. 30 2025
-0.07
-0.08
0.01
Beat
112.9
​​Mar. 31 2025
-0.10
-0.10
-0.07
Beat
28.2
Dec. 31 2024
-0.13
-0.13
-0.09
Beat
29.3​
Sep. 30 2024
-0.17
-0.16
-0.18
Missed
-9.4
Jun. 30 2024
-0.19
-0.19
-0.17
Beat
9.9
This summary was machine generated August 4 at 14:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)